Company Description
Ironwood Pharmaceuticals, Inc., a healthcare company, focuses on the development and commercialization of gastrointestinal (GI) products.
It markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and Mexico, as well as under the CONSTELLA name in the Canada and European Union.
The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis; and CNP-104, an immune nanoparticle for the treatment of biliary cholangitis.
The company has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide.
The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008.
Ironwood Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Boston, Massachusetts.
| Country | United States |
| IPO Date | Feb 3, 2010 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Sector | Healthcare |
| Employees | 267 |
| CEO | Thomas A. McCourt |
Contact Details
Address: 100 Summer Street Boston, Massachusetts United States | |
| Website | https://www.ironwoodpharma.com |
Stock Details
| Ticker Symbol | IRWD |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001446847 |
| CUSIP Number | 46333X108 |
| ISIN Number | US46333X1081 |
| Employer ID | 04-3404176 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Thomas A. McCourt | Chief Executive Officer, Principal Financial Officer & Director |
| John Minardo | Senior Vice President, Chief Legal Officer & Secretary |
| Beth Calitri | Vice President of Corporate Communications & Media Relations |
| Dr. Michael Shetzline M.D., Ph.D. | Chief Medical Officer, Senior Vice President and Head of Research & Drug Development |
| Dr. Rosario Lobrutto M.B.A., M.S., Ph.D. | Vice President & Global Head of Technical Operations |
| Dr. Susanna Y. Huh M.D., M.P.H. | Vice President & Head of Clinical Development |
| Greg Martini | Vice President of Strategic Finance & Investor Relations |
| Mike Nanfito | Vice President of Sales & Sales Excellence |
| Ronald Silver | Corporate Controller & Principal Accounting Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Dec 18, 2024 | 4 | Filing |
| Dec 05, 2024 | 8-K | Current Report |
| Nov 20, 2024 | 4 | Filing |
| Nov 20, 2024 | 4 | Filing |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 13, 2024 | SCHEDULE 13G | Filing |
| Nov 12, 2024 | 8-K | Current Report |
| Nov 12, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 08, 2024 | SC 13G/A | [Amend] Statement of acquisition of beneficial own... |
| Nov 07, 2024 | 10-Q | Quarterly Report |